Back to Search Start Over

OXavidin for tissue targeting biotinylated therapeutics.

Authors :
De Santis R
Albertoni C
Rosi A
Leoni B
Petronzelli F
D'Alessio V
Nucera E
Salvatori G
Paganelli G
Verdoliva A
Carminati P
Nuzzolo CA
Source :
Journal of biomedicine & biotechnology [J Biomed Biotechnol] 2009; Vol. 2009, pp. 921434. Date of Electronic Publication: 2010 Jan 10.
Publication Year :
2009

Abstract

Avidin is a glycoprotein from hen egg white that binds biotin with very high affinity. Here we describe OXavidin, a product containing aldehyde groups, obtained by ligand-assisted sugar oxidation of avidin by sodium periodate. OXavidin chemically reacts with cellular and tissue proteins through Schiff's base formation thus residing in tissues for weeks while preserving the biotin binding capacity. The long tissue residence of OXavidin as well as that of OXavidin/biotinylated agent complex occurs in normal and neoplastic tissues and immunohistochemistry shows a strong and homogenous stromal localization. Once localized in tissue/tumor, OXavidin becomes an "artificial receptor" for intravenous injected biotin allowing tumor targeting with biotinylated therapeutics like radioisotopes or toxins. Moreover, present data also suggest that OXavidin might be useful for the homing of biotinylated cells. Overall, OXavidin exhibits a remarkable potential for many different therapeutic applications.

Details

Language :
English
ISSN :
1110-7251
Volume :
2009
Database :
MEDLINE
Journal :
Journal of biomedicine & biotechnology
Publication Type :
Academic Journal
Accession number :
20130784
Full Text :
https://doi.org/10.1155/2009/921434